Hepatocellular carcinoma
Conditions
Interventions
The glucagon-like peptide-1 receptor agonist group:None
The group of dipeptidyl peptidase-4 inhibitors:None
Sponsors
The Third Affiliated Hospital of Naval Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adults over 18 years old. 2. Histologically confirmed hepatocellular carcinoma (HCC) and with R0 resection performed. 3. Type 2 diabetes that was recorded either before or on the day of the surgery. 4. The first qualified prescription of GLP-1RA or DPP-4i was recorded within 0-90 days after the surgery. 5. The patient had not previously used GLP-1RA or DPP-4i drugs based on their previous medical history and medication record.
Exclusion criteria
Exclusion criteria: 1. Absence of HCC pathological features, R1/R2 resection range, or evidence of major vascular invasion during or before the operation as indicated by imaging examinations, surgical findings, and/or pathological results. 2. History of liver transplantation. 3. Type 1 diabetes or pancreatic diabetes, or documented acute pancreatitis before the first qualified prescription. 4. Administration of dual prescriptions of GLP-1RA and DPP-4i on the same day within the confirmation window. 5. Key data quality issues that prevent reliable allocation or result determination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Fixed-time-point absolute risk of recurrence and absolute risk difference;Restricted mean survival time difference;Noncancer-related trauma or accidental injury hospitalization;At least 5% weight loss at approximately 12 months after surgery; | — |
Countries
China
Contacts
Public ContactCheng Shuqun
The Third Affiliated Hospital of Naval Medical University
Outcome results
None listed